The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
The transition period for permitted indications ended on 5 March 2021.
On 6 March 2018, the TGA implemented a list of permitted indications for medicines listed under section 26A of the Therapeutic Goods Act 1989 (the Act). All new listed medicines included in the Australian Register of Therapeutic Goods (ARTG) since this time have only been able to use permitted indications.
The list of permitted indications can be accessed via the Permissible Indications Determination (Determination) or via the TGA Business Services website.
Introduction of the permitted indications reform implements one of the Government's reforms to the regulatory framework for complementary medicines arising from the Medicines and Medical Devices Regulation Review (MMDR).